{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:09 23:24:50.411",
            "Expression": "NCT02918123",
            "NStudiesAvail": 430269,
            "NStudiesFound": 1,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 1,
            "FieldList": [
                  "DesignTimePerspective",
                  "DesignWhoMasked",
                  "DetailedDescription",
                  "DispFirstPostDate",
                  "DispFirstPostDateType",
                  "DispFirstSubmitDate",
                  "DispFirstSubmitQCDate",
                  "EligibilityCriteria",
                  "EnrollmentCount",
                  "EnrollmentType",
                  "EventGroupDeathsNumAffected",
                  "EventGroupDeathsNumAtRisk",
                  "EventGroupDescription",
                  "EventGroupId",
                  "EventGroupOtherNumAffected",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [],
                        "DetailedDescription": [
                              "This is a phase 1, single center, randomized, open label, study of safety of FURESTEM-CD Inj. in subjects with moderate to severe plaque psoriasis.\n\nApproximately 9~18 subjects will be administrated FURESTEM-CD Inj.\n\nFURESTEM-CD Inj. is composed of allogeneic hUCB-MSC(human Umbilical Cord Blood derived-Mesenchymal Stem cell). hUCB-MSCs are mesenchymal stem cells from umbilical cord blood. Mesenchymal stem cells are well-known for immunosuppression, anti-inflammatory ability and capable of differentiating into a wide range of cell types. Therefore, FURSTEM-CD Inj. has huge possibility as cell therapy products for plaque-type Psoriasis patients."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\n19-65 years old(both sexes)\nHave been diagnosed with plaque-type psoriasis at least 6 months prior to screening (subjects with concurrent psoriatic arthritis[PsA] may be enrolled)\nPsoriasis Area and Severity Index (PASI) score >= 12 at screening\nBSA(Body Surface Area) >= 10 percentage at screening\n\nHave had at least one of the following conventional systemic agent for the treatment of psoriasis,\n\nMTX, Cyclosporine, Photochemotherapy, TNF-alpha inhibitor or IL-12/IL-23 inhibitor\nSubject who would agree to avoid prolonged sun exposure, use of tanning booths or other ultraviolet light sources during the clinical study\nSubject who understands and voluntarily signs the informed consent form\n\nExclusion Criteria:\n\nSubject who has other types of psoriasis (eg. Erythrodermic, guttate, or pustular)\nHave a history of chronic or recurrent infectious disease\nHave received phototherapy or any systemic medications/treatments within 4 weeks of screening that could affect psoriasis or PASI evaluation\nHave used topical medications/treatments within 2 weeks of screening that could affect psoriasis or PASI evaluation\nHave used any systemic immunosuppressants within 4 weeks of screening\n\nHave been administered with the following biological agents that could affect plaque-type psoriasis\n\nEtanercept - within 4 weeks of screening\nAdalimumab, alefacept, infliximab - within 2 months of screening\nUstekinumab - within 4 weeks of screening\nOther investigational biological agents - within 4 weeks of screening/five half-lives(whichever was longer)\nPregnant, breast-feeding women or women who plan to become pregnant during this study (Females of childbearing potential must have a negative urine pregnancy test at screening)\nHave been administered any types of investigational drugs within the previous 4 weeks or five half-lives of the investigational agent, whichever is longer\nSubject who already took or need to take medicine which is prohibited during the clinical study\nSubject who has sever dyshepatia (Creatinine value \u2265 2X Upper limit of the normal range at screening test)\nSubject who has severe renal dysfunction (AST/ALT value \u2265 2X Upper limit of the normal range at screening test)\nHave received a live viral or bacterial vaccination within 3 months of screening\nHave had a BCG(Bacillus Calmette-Gu\u00e9rin) vaccination within 12 months of screening\nHave a transplanted organ(with the exception of a corneal transplant > 3 months prior to screening)\nHave any known malignancy or have a history of malignancy\nHave a history of hypersensitivity, heavy metal poisoning etc. to drugs which are composed of similar components or have undergone allergy immunotherapy previously for prevention of anaphylactic reactions\nHave had a serious infection (eg. Sepsis, pneumonia or pyelonephritis), or have been hospitalized or received IV antibiotics for an infection during the 2 months prior to screening\nPositive for Hepatitis B virus(HBV) surface antigen or anti-Hepatitis C virus antibody screening\nKnown to have had a substance abuse(drug or alcohol) problem within 12 months of screening\nSubject who experienced stem cell therapy\nAny other conditions which the PI suspect the patient to be unsuitable for the clinical"
                        ],
                        "EnrollmentCount": [
                              "9"
                        ],
                        "EnrollmentType": [
                              "Anticipated"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT02918123"
                        ]
                  }
            ]
      }
}